# US 2013/0158008 A1 · Solid ivabradine-containing composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158008 A1
- Document ID: US20130158008A1
- Status: Published application
- Kind: A1
- Application number: 13/704,580
- Filed: 2011-06-14
- Published: 2013-06-20
- Earliest claimed: 2010-06-14
- Assignees: ratiopharm GmbH
- Inventors: Dominique Meergans; Daniela Stumm; Jens Geier
- Web page: https://patentgrep.com/patent/US20130158008A1

## CPC

- A61K 47/38: Cellulose; Derivatives thereof
- A61K 9/0002: {Galenical forms characterised by the drug release technique; Application systems commanded by energy}
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 9/146: {with organic macromolecular compounds}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2095: {Tabletting processes}
- A61K 9/2846: {Poly(meth)acrylates}
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- C07C 55/14: Adipic acid
- C07D 223/16: Benzazepines; Hydrogenated benzazepines
- Y10T 428/2982: Particulate matter [e.g., sphere, flake, etc.]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

The present invention relates to a solid composition containing ivabradine or a pharmaceutically acceptable salt thereof. Further, the invention relates to a method for the preparation of such a composition as well as a pharmaceutical product comprising such a composition.

## Claims

### Claim 1

A solid composition containing ivabradine or a pharmaceutically acceptable salt thereof as active substance in combination with at least one pharmaceutically acceptable excipient characterized in that the excipient and the active substance are present in a homogeneous, molecularly disperse mixture, wherein the pharmaceutically acceptable excipient is selected from the group consisting of sucrose, sorbitol, xylitol, polyethylene glycol, polyoxyethylene glycol monosterate, glycerol polyethylene glycol ricinolate, macrogol glycerol stearate, glycerol palmitol stearate, macrogol glycerol laurate, polyethylene glycol cetylstearyl ether, glycerol monostearate, polyvinylpyrrolidone, cellulose derivatives, copovidone, and ethylene oxide-propylene oxide block-copolymers.

### Claim 2 (depends on 1)

The solid composition according to claim 1, wherein less than 15% by weight, of the active substance, based on its total amount, present in the form of particles.

### Claim 3 (depends on 1)

The solid composition according to claim 1, wherein the weight ratio of active substance, based on the free base, to excipient is in the range of 1:1 to 1:1,000.

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6 (depends on 1)

A method for the preparation of a solid composition according to claim 1, said method comprising the step of mixing of excipient and active substance to a homogeneous, molecularly disperse mixture.

### Claim 7 (depends on 6)

The method according to claim 6, wherein mixing is done in a combined melt of excipient and active substance.

### Claim 8 (depends on 7)

The method according to claim 7, wherein mixing is done by melt extrusion.

### Claim 9 (depends on 6)

The method according to claim 6, wherein mixing is done by dissolving excipient and active substance in a solvent and subsequently evaporating the solvent.

### Claim 10 (depends on 6)

A solid composition obtained in accordance to a method of claim 6.

### Claim 11 (depends on 6)

A pharmaceutical product containing a composition according to claim 6.

### Claim 12 (depends on 11)

The pharmaceutical product according to claim 11, wherein said product is selected from the group consisting of capsules, tablets, tablets that disintegrate in the mouth, retarded release tablets, pellets, and granules.

### Claim 13 (depends on 1)

The solid composition according to claim 1, wherein less than 5% by weight of the active substance, based on its total amount, is present in the form of particles.

### Claim 14 (depends on 1)

The solid composition according to claim 1, wherein the weight ratio of active substance, based on the free base, to excipient is in the range of 1:10 to 1:50.

### Claim 15 (depends on 10)

A pharmaceutical product containing a composition according to claim 10.

### Claim 16 (depends on 15)

The pharmaceutical product according to claim 15, wherein said product is selected from the group consisting of capsules, tablets, tablets that disintegrate in the mouth, retarded release tablets, pellets, and granules.
